None listed
Conditions
Brief summary
This study aims to evaluate the effect of a 12-week Tai Chi programme on people with COPD. We hypothesize that after 12-week programme, participants receiving Tai Chi training will have better cognitive and physical performance when compared with control groups.
Interventions
Tai Chi Group:
Participants, in a group of 4-6, will join 2 supervised sessions of Tai Chi (Sun-Style Tai Chi) per week supervised by a research personnel with experience of practicing Sun-Style Tai Chi in an outpatient setting. Each session will last for 60 minutes including warm up, Tai chi and cool down.
All participants are advised to practice daily at home following what they have practiced in the supervised session with practice duration similar to supervised session. All participants wil
Tai Chi Group: Participants, in a group of 4-6, will join 2 supervised sessions of Tai Chi (Sun-Style Tai Chi) per week supervised by a research personnel with experience of practicing Sun-Style Tai Chi in an outpatient setting. Each session will last for 60 minutes including warm up, Tai chi and cool down. All participants are advised to practice daily at home following what they have practiced in the supervised session with practice duration similar to supervised session. All participants will have an accelerometer (to be worn at wrist) to record their level of physical activities and an exercise logbook for recording.The whole program will last for 12 weeks.
Sponsors
Dr. Shirley Ngai
Study design
Allocation
Randomised controlled trial
Intervention model
Factorial
Primary purpose
Treatment
Masking
Blinded (masking used) (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
55 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Participants aged more than or equal to 55; with medical diagnosis of COPD, following the guidelines of Global Initiative for Chronic Obstructive Lung Disease (GOLD), with a ratio of post-bronchodilator forced expiratory flow volume in one second (FEV1)/ Forced Vital Capacity (FVC) of <70%; and GOLD stage II or above (i.e. FEV1<80% predicted)
Exclusion criteria
Participants with confirmed diagnosis of cognitive impairment such as Alzheimer’s disease; or neurological disorders such as stroke; or Diabetes mellitus that may influence blood flow at cerebral and tissue (i.e. muscle) level; or Unstable cardiovascular disease or recent musculoskeletal disorders that may affect their exercise performance
Outcome results
None listed